- Home
- STEW vs ARDX Comparison
STEW vs ARDX Comparison
Compare STEW & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEW
- ARDX
- Stock Information
- Founded
- STEW 1972
- ARDX 2007
- Country
- STEW United States
- ARDX United States
- Employees
- STEW N/A
- ARDX N/A
- Industry
- STEW Investment Managers
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- STEW Finance
- ARDX Health Care
- Exchange
- STEW Nasdaq
- ARDX Nasdaq
- Market Cap
- STEW 1.6B
- ARDX 1.3B
- IPO Year
- STEW N/A
- ARDX 2014
- Fundamental
- Price
- STEW $16.52
- ARDX $4.82
- Analyst Decision
- STEW
- ARDX Strong Buy
- Analyst Count
- STEW 0
- ARDX 8
- Target Price
- STEW N/A
- ARDX $10.19
- AVG Volume (30 Days)
- STEW 84.5K
- ARDX 5.8M
- Earning Date
- STEW 01-01-0001
- ARDX 05-01-2025
- Dividend Yield
- STEW 3.71%
- ARDX N/A
- EPS Growth
- STEW N/A
- ARDX N/A
- EPS
- STEW 1.44
- ARDX N/A
- Revenue
- STEW N/A
- ARDX $333,615,000.00
- Revenue This Year
- STEW N/A
- ARDX $15.76
- Revenue Next Year
- STEW N/A
- ARDX $34.54
- P/E Ratio
- STEW $10.34
- ARDX N/A
- Revenue Growth
- STEW N/A
- ARDX 168.06
- 52 Week Low
- STEW $11.97
- ARDX $4.02
- 52 Week High
- STEW $14.94
- ARDX $9.33
- Technical
- Relative Strength Index (RSI)
- STEW 49.01
- ARDX 49.22
- Support Level
- STEW $16.31
- ARDX $4.51
- Resistance Level
- STEW $16.90
- ARDX $4.70
- Average True Range (ATR)
- STEW 0.51
- ARDX 0.31
- MACD
- STEW -0.01
- ARDX 0.03
- Stochastic Oscillator
- STEW 63.07
- ARDX 81.12
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.